Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
BOSTON, Sept. 19, 2024 (GLOBE NEWSWIRE) — Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company’s scientific poster presentation from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting taking place from September 18 to 20, 2024 in Copenhagen, Denmark.
19 Sep 00:00 · Financial Post